Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules
- 31 December 2008
- journal article
- Published by Elsevier in International Journal of Research in Marketing
- Vol. 25 (4) , 247-260
- https://doi.org/10.1016/j.ijresmar.2008.08.002
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Economic Consequences of Underuse of Generic Drugs: Evidence from Medicaid and Implications for Prescription Drug Benefit PlansHealth Services Research, 2003
- The Impact of Generic Drug Competition on Brand Name Market Shares – Evidence from Micro DataReview of Industrial Organization, 2001
- The Importance of Doctors’ and Patients’ Preferences in the Prescription DecisionJournal of Industrial Economics, 2000
- Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelinesJournal of Psychopharmacology, 2000
- The impact of generic goods in the pharmaceutical industryHealth Economics, 1999
- Generic Entry and the Pricing of PharmaceuticalsJournal of Economics & Management Strategy, 1997
- Using Extremes to Design Products and Segment MarketsJournal of Marketing Research, 1995
- Pricing, Patent Loss and the Market for PharmaceuticalsSouthern Economic Journal, 1992
- Brand Choice, Purchase Incidence, and Segmentation: An Integrated Modeling ApproachJournal of Marketing Research, 1992
- Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical IndustryBrookings Papers on Economic Activity. Microeconomics, 1991